I think the fact that the Virology Conference is virtual plays heavily into IPIX's favor. I went over the Conference schedule and the GMU presentation is not listed in the top couple of levels of presentations which leads me to believe it would not have gotten that much attention at an in-person conference due to attendees being overwhelmed with what is considered more important presentations.

Being virtual, the attendees can listen to ALL the presentations over a longer period of time as they see fit. This should allow the GMU presentation to be listened to by most of the attendees IMO.

Many of the top level presentations are quite specific in addressing what IMO are very narrow areas of interest, whereas the GMU Brilacidin talk should be of interest to ALL attendees, being the introduction of a new arm of medicine and a specific drug that has yet to be defeated by any bacteria or virus. A broad spectrum wonder drug that has yet to meet any resistance to it. This is the goal of the conference, to make known the cutting edge of virology and that is spelled Brilacidin.

I think the GMU presentation will gob smack most of the virologists but I also believe they will be looking forward to it based on the earlier peer review that was sent out to them.

Whether the conference plays that heavily into IPIX's favor I have some doubts, but it should make Brilacidin a subject that all worldwide virologists will want to study further.

IPIX entered the CV19 fray for expanded Brilacidin broadcasting to the medical world, this conference should provide a major step in further accomplishing that goal.